▎药明康德/报道

药明康德录用Frederick H. Hausheer博士为首席医学官 [原创文章：www.ii77.com]

[转载出处：www.ii77.com]

中国上海，美国德克萨斯州奥斯汀，2019年4月8日——药明康德今天公布Frederick H. Hausheer博士已正式到场公司，担当首席医学官（Chief Medical Officer）。

Hausheer博士将主导药明康德临床斥地办事买卖在美国、中国以及全球各地的医疗、科学及运营治理工作。此外，他将为公司供应医学和临床斥地方面的计谋指导，以增强各买卖部门与合作伙伴间的慎密关联，促进从临床前转化研究与斥地，到首次人体临床试验（FIH），再到为客户制订I-IV期临床斥地规划的一站式办事..的无缝跟尾。

Hausheer博士在全球肿瘤临床药物斥地、转化科学和医学方面拥有跨越30年的贸易及学术经验。他在转化研究/新药临床试验申请、临床试验设计、贸易临床斥地等范畴经验雄厚，曾普遍介入从新药临床试验申请前期，到I-III期临床试验的监管沟通工作，项目局限涉及欧、美、中、日等多个国度和区域。

 “我们非常迎接Hausheer博士加盟并担当首席医学官，”药明康德联席首席执行官胡正国师长透露，“Hausheer博士在全球肿瘤药物斥地、临床研究及医疗范畴等方面有着雄厚的经验。相信他的到场，将进一步增加公司在全球的临床办事能力和规模，更好地赋能全球客户，助推更多新药、好药早日问世，造福恢弘病患。”

在到场药明康德之前，Hausheer博士在多家生物制药公司担当首席执行官和首席医学官，他曾是BioNumerik Pharmaceuticals公司的创始人兼董事长。他照样摩根大通（JP Morgan Chase）、约翰霍普金大学惠特克研究所（Whittaker Institute at Johns Hopkins）、美国国度癌症研究所（National Cancer Institute, NCI）等多家组织机构的贸易咨询..成员。在他职业生涯早期，Hausheer博士曾在NCI的实验治疗部、决议收集小组和机构审查..任职，普遍介入了浩瀚国度级和国际级的临床I-III期试验项目，项目内容涉及肺癌、乳腺癌、卵巢癌以及其他恶性肿瘤的立异疗法。

Hausheer博士在密苏里大学医学院获得医学博士学位，卒业后在约翰霍普金斯肿瘤中心任职，专注于立异实验疗法和药理学。今朝Hausheer博士还在密苏里大学以及约翰霍普金斯肿瘤中心内科肿瘤科担当..传授。此外，他照样400多项美国及国际专利的发现者或配合发现人。

关于药明康德

药明康德（股票代码：603259/2359.HK）是国际领先的开放式能力与手艺..公司，为全球制药及医疗工具等范畴供应从药物发现、斥地到市场化的全方位一体化的实验室研发和生产办事。本着以研究为首任，以客户为中心的宗旨，药明康德经由高性价比、高效率的办事..匡助全球客户缩短药物及医疗工具研发周期、降低研发成本。药明康德..涵括小分子药物研发及生产、细胞疗法与基因疗法研发生产、医疗工具测试等，正承载着来自全球30多个国度的3500多家立异合作伙伴的数千个研发立异项目，致力于将最新和最好的医药和健康产物带给全球病患，实现“让世界没有难做的药，难治的病”的妄想。更多信息，请接见公司网站：www.wuxiapptec.com

---

WuXi AppTec Appoints Dr. Frederick H. Hausheer as Chief Medical Officer

SHANGHAI and AUSTIN, Texas, April 8, 2019 -- WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, today announces the appointment of Dr. Frederick H. Hausheer as Chief Medical Officer for the company. 

In this executive role, Dr. Hausheer will provide medical, scientific and operational leadership to WuXi Clinical operations in the United States, China and other territories. In addition, he will play a key role in forging and maintaining strong connections between our customers and WuXi’s business units by providing inputs on medical and clinical development strategies aimed at seamless integration from preclinical translational research and development into first-in-human studies, as well as for Phase I-IV clinical development plans for our customers.

Dr. Hausheer brings more than 30 years' experience in global oncology clinical drug development and translational science and medicine in commercial and academic settings. He has extensive experience in translational/IND programs, clinical trial design, commercial clinical development, and involvement in regulatory interactions for novel agents spanning from pre-IND and Phase I-III development in the United States, China, Europe, Japan and other territories.

“We’re very excited to welcome Dr. Hausheer onboard as our Chief Medical Officer,” said Mr. Edward Hu, Co-CEO of WuXi AppTec. “Dr. Hausheer’s rich experience in global oncology clinical drug development and translational science and medicine makes him ideally suited to taking this role. We are confident in his leadership to strengthen WuXi’s clinical development capabilities and capacity globally, and enable more customers to develop better medicine faster to benefit patients around the world.”

Prior to joining WuXi, Dr. Hausheer held CEO and CMO positions with several Biopharma companies, and was the Founder and Chairman of BioNumerik Pharmaceuticals. He has also served as a business advisory board member to JP Morgan Chase, the Whittaker Institute at Johns Hopkins, and the National Cancer Institute. Early in his career he served on the National Cancer Institute (NCI) Experimental Therapeutics Section, the NCI Decision Network Panel, and the NCI Institutional Review Board, followed by extensive involvement in national and international Phase I-III clinical trials involving novel treatments for lung, breast, ovarian and other malignancies.

Dr. Hausheer obtained his MD at the University of Missouri, School of Medicine and then became a faculty member at the Johns Hopkins Oncology Center, where he focused on the development of novel experimental therapeutics and pharmacology. He currently holds adjunct professorships at the University of Missouri in Internal Medicine and Oncology and The Johns Hopkins Oncology Center in Medical Oncology. He is an inventor/co-inventor on more than 400 issued United States and international patents. 

About WuXi AppTec

WuXi AppTec is a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities such as small molecule R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, and medical device testing, WuXi platform is enabling more than 3,500 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi's dream that "every drug can be made and every disease can be treated." Please visit: http://www.wuxiapptec.com

本文来自药明康德微信团队，迎接转发到同伙圈，回绝转载到其他..；若有开设白名单需求，请在文章底部留言；若有其他合作需求，请关联wuxi_media@wuxiapptec.com